Prognostic impact of lymphovascular invasion in lymph node-negative superficial esophageal squamous cell carcinoma. Issue 11 (18th March 2019)

• Record Type: Journal Article
• Authors: Oguma, J; Ozawa, S; Kazuno, A; Yamamoto, M; Ninomiya, Y; Yatabe, K; Makuuchi, H; Ogura, G
• Is Part Of: Diseases of the esophagus. Volume 32:Issue 11(2019)
• Publication Date: 2019-03-18
• Subjects: lymphovascular invasion -- prognostic factor -- superficial esophageal squamous cell carcinoma; Esophagus -- Diseases -- Periodicals; 616.32
• DOI: 10.1093/dote/doz001
• Languages: English
• ISSNs: 1120-8694

Abstract

SUMMARY: The relationship between lymphovascular invasion (LVI) and prognosis in patients with superficial esophageal squamous cell carcinoma (SESCC) is unclear. The aim of this study is to evaluate prognostic factors in patients with lymph node-negative SESCC. A total of 195 patients with pathologically confirmed T1a-MM, T1b, and lymph node-negative SESCC were retrospectively reviewed in this study. Overall, the disease-free survival (DFS) rate was poorer in the lymphatic invasion-positive group than in the lymphatic invasion-negative group ( p = 0.002) and a multivariate analysis suggested that lymphatic invasion was the only independent prognostic factor of DFS in patients with lymph node-negative SESCC (HR = 4.075, p = 0.005). Distant organ recurrence occurred in one patient (1/52, 1.9%) in the T1b-SM2 group and in six patients (6/61, 9.7%) in the T1b-SM3 group; all of these patients had LVI. LVI-positive patients had a poorer DFS than invasion-negative patients in the T1b-SM2 and SM3 groups ( p = 0.026), and a multivariate analysis suggested that LVI was the only independent prognostic factor of DFS in patients with lymph node-negative SM2 and SM3 SESCC (HR = 5.165, p = 0.031). Lymph node-positive patients had a significantly poorer DFS rate than lymph node negative and LVI positive patients among the SM2 and SM3 SESCC patients ( p = 0.018). The present results suggested that LVI was an independent prognostic factor in patients with SM2 and SM3 lymph node-negative SESCC; however their prognosis was not worse than that of patients with lymph node-positive SM2 and SM3 SESCC, for whom adjuvant therapy is indicated as a standard treatment.